Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Plus BIO Conference Goes Digital And More

 
• By Scrip Team

Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.

Coronavirus_Restricted_Area
Novartis is joining others in launching Phase III trials for therapies to treat acutely ill COVID-19 patients

More from Archive

More from Scrip